Novo Nordisk filed suit against Eli Lilly on Tuesday in the U.S. District Court for the District of New Jersey, alleging violations of federal and state false advertising and unfair competition laws, including the Lanham Act, over direct-to-consumer campaigns for Zepbound and Mounjaro.
The core allegation is specific and easy to state. Lilly's ads allegedly compare the highest injectable doses of its medicines against lower doses of Novo's. In the Zepbound comparison, that means Zepbound's 10 and 15 milligram doses against Wegovy at 1.7 and 2.4 milligrams, omitting the 7.2 milligram Wegovy dose the FDA approved in March 2026, which showed roughly 19% average body weight reduction. In the diabetes comparison, Mounjaro's 15 milligram dose is set against Ozempic at 1 milligram, rather than the 2 milligram maintenance dose approved more than four years ago.
One television spot cited in the complaint presents a side-by-side showing 50 pounds lost on average with Lilly's drug against 33 pounds on the 2.4 milligram dose of Novo's.
Novo is seeking a permanent injunction, corrective advertising, and damages, and says it will move for a preliminary injunction if Lilly does not pull the campaigns voluntarily. It sent a cease-and-desist first.
Why Lilly's position is not weak
The obvious reading is that Lilly cherry-picked. Its actual defense is more interesting, and it rests on a principle of evidence that favors it.
Lilly says it stands behind its advertising as truthful, transparent, and grounded in the most direct scientific evidence available, and specifically that its Zepbound ads rely on a head-to-head clinical trial against Wegovy, which remains the only direct study between the two products.
That matters more than it might appear. In clinical evidence, head-to-head randomized trials sit at the top of the hierarchy for comparative claims. Comparing results across separate trials, the alternative, is notoriously unreliable: different populations, entry criteria, trial durations, background care, and measurement conventions can produce apparent differences that reflect trial design rather than drug effect. Regulators and evidence-review bodies discount cross-trial comparisons for exactly this reason.
So Lilly's position is that it used the only direct comparison in existence, and that the alternative Novo prefers would require an indirect comparison of the sort the field generally treats as unreliable.
Novo's position is that the direct comparison is now stale in the one dimension that matters most, dosing, because a substantially more effective dose of its drug has since been approved.
Both of those are true statements. That is what makes this a genuine dispute rather than a straightforward case of deception.
The structural problem underneath
The reason this conflict exists is that evidence generation is slower than label changes, and nothing about that is going to improve.
The head-to-head trial was designed and conducted when 2.4 milligrams was the maximum approved Wegovy dose. It answered the question that existed at the time. When the FDA approved the 7.2 milligram dose in March 2026, that trial became permanently incapable of answering the current comparative question, and generating a new head-to-head trial at current doses takes years and enormous expense.
That leaves a persistent gap between the best direct evidence and the products actually on the market. Any advertiser in that gap faces a choice between citing rigorous evidence about a superseded configuration or making a weaker inference about the current one.
This is not unique to these two companies. It will recur in every therapeutic area where products iterate faster than comparative trials can be run, which is increasingly most of them.
The footnote question, and the legal standard
The complaint's sharper point may be the one about disclosure rather than data selection. Novo alleges that Lilly acknowledges the existence of the higher Wegovy dose in footnotes that are ambiguous and virtually invisible.
That framing targets the right legal question. Lanham Act false advertising claims do not require a statement to be literally false. An advertisement can be actionable if it is literally true but misleading in its overall impression to consumers. A qualifier technically present but functionally unreadable does not necessarily cure a misleading impression, and courts have repeatedly said so in other industries.
Whether these particular footnotes clear that bar is a factual question that will turn on evidence, likely including consumer perception surveys, which is why Novo says it will present evidence that consumers are actually being confused. Consumer confusion is not assumed under the statute; it is demonstrated.
Why this is a direct-to-consumer problem specifically
Novo's complaint makes an argument worth extracting, because it points at something larger than either company.
The suit contends that the campaigns are harmful because consumers rely on advertising to form their understanding of these drugs, unlike healthcare professionals, who have access to the full scientific evidence. The ads ran during major sporting broadcasts and on TikTok and Facebook.
That is the strongest version of Novo's case and also an argument about the practice itself. A physician comparing these drugs reads trial data, understands dose-response relationships, and knows what a 2.4 milligram comparator implies. A patient watching a commercial during a sporting event has none of that context and no way to evaluate whether the doses being compared are the ones they would receive.
The United States and New Zealand are essentially alone in permitting direct-to-consumer prescription drug advertising, and this dispute illustrates why other countries decline: comparative efficacy claims are difficult to convey accurately to an audience without the training to interpret them, and the incentive to present favorable framing is enormous. Novo, it should be noted, advertises heavily too, so the argument is being deployed selectively.
What to watch
Three things will indicate how this resolves.
Whether Lilly pulls the ads voluntarily is the near-term signal, since Novo has said it will seek a preliminary injunction otherwise. Preliminary injunction proceedings move fast and require Novo to show likely success on the merits, which would produce an early judicial read on the dose-comparison question.
Whether Novo's consumer confusion evidence is persuasive will largely determine the outcome, because that is the element the statute actually turns on.
And whether either company commits to a new head-to-head trial at current maximum doses. That would resolve the underlying question definitively, and neither has an obvious incentive to run it unless confident of the result, which is itself informative. For patients, the practical takeaway is narrower than the litigation. Weight loss on these drugs is dose-dependent, the maximum approved doses have changed recently for at least one product, and an advertisement comparing two medicines is not a substitute for asking a clinician which dose of which drug is appropriate for a specific person.